Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products

What this Trial Is About

This research aims to monitor patients previously treated with Replimune oncolytic immunotherapy products, including RP1, RP2, and RP3, to assess long-term safety outcomes. It focuses on detecting delayed adverse events such as new cancers, worsening neurological or autoimmune disorders, blood disorders, infections linked to RPx products, and herpetic-like infections. The study is observational and involves patients who completed or withdrew from a prior Replimune-sponsored parent study. There are no treatments or interventions given in this study. Participants will be followed for five years after enrollment with check-ins every three months. These contacts may occur in person, by phone, video conference, or other technologies. If a herpetic infection is suspected, participants may be asked to provide samples from the affected area or other biological samples like blood or urine. During the study, researchers will evaluate safety by reviewing any delayed risks or adverse events related to the RPx products. Participants will be regularly contacted to monitor their health status, with outcome measures assessed every three months over the five-year period. This long-term follow-up helps identify any late effects of the treatments without requiring any study treatments or procedures beyond monitoring and sample collection when needed.

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3